Company intelligence / Profile preview

Supernus Pharmaceuticals, Inc.

Rockville, Maryland, United Statessupernus.com ↗

Ownership: Public · SUPN
Development stage: Commercial

Overview

Supernus has multiple marketed products for CNS conditions and several candidates in late-stage development. In February 2025, they received FDA approval for ONAPGO (apomorphine hydrochloride) injection for Parkinson's disease. In January 2025, they received FDA approval for the label for Qelbree (viloxazine extended-release capsules).

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

10 assets

viloxazine

Approved

9 more assets in the full pipeline.

Request access →

Partnerships

Britannia Pharmaceuticals LimitedZambon S.p.A

Financials

Market cap: $2.4B
Total revenue: $219.1M
Enterprise value: $2.1B

Beyond the preview

Go deeper on Supernus Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Supernus Pharmaceuticals, Inc..

Explore the full profile